Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR110894D add-on to donepezil in mild to moderate Alzheimer's disease
2010-022596-64Phase 2Completed
- Sponsor
- Sanofi
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SAR110894 in Alzheimer's disease (AD) (4 arms), sponsored by Sanofi. Primary endpoint: Change from baseline to week 24 in ADAS-Cog 13 11-item standard total score. Started Nov 2010; status: completed.
02
Drugs
SAR110894
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-022596-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022596-64.